{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:31:36Z","timestamp":1786710696086,"version":"build-2736575974"},"reference-count":152,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.dld.2026.06.019","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:28:27Z","timestamp":1784838507000},"page":"1124-1138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["AISF practice guidance on the treatment of primary biliary cholangitis: A 2026 update"],"prefix":"10.1016","volume":"58","author":[{"given":"Alessio","family":"Aghemo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Calvaruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Cazzagon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cristoferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9028-4040","authenticated-orcid":false,"given":"Daphne","family":"D\u2019Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0019-1153","authenticated-orcid":false,"given":"Roberta","family":"D\u2019ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6366-6836","authenticated-orcid":false,"given":"Francesca","family":"Fianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Germani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8526-837X","authenticated-orcid":false,"given":"Edoardo Giovanni","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Labanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0561-7902","authenticated-orcid":false,"given":"Ana","family":"Lleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-3948","authenticated-orcid":false,"given":"Giuseppe","family":"Marrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Marzioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9518-4751","authenticated-orcid":false,"given":"Grazia","family":"Pennisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Ponziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2089-4139","authenticated-orcid":false,"given":"Cristina","family":"Rigamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0761-1333","authenticated-orcid":false,"given":"Vincenzo","family":"Ronca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Terracciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8350-1155","authenticated-orcid":false,"given":"Francesco","family":"Tovoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto Vespasiani","family":"Gentilucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0769-1767","authenticated-orcid":false,"given":"Mauro","family":"Vigan\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2026.06.019_bib0001","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0002","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.dld.2024.05.002","article-title":"Position paper of the Italian Association for the Study of the Liver (AISF): management and treatment of primary biliary cholangitis","volume":"56","author":"Carbone","year":"2024","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2026.06.019_bib0003","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.29717","article-title":"Milder disease stage in patients with primary biliary cholangitis over a 44-year period: a changing natural history","volume":"67","author":"Murillo Perez","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0004","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/jgh.15329","article-title":"Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis","volume":"36","author":"Lv","year":"2021","journal-title":"J Gastro Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0005","article-title":"Incidence and prevalence of primary biliary cholangitis in the Netherlands \u2013 a nationwide cohort study","volume":"6","author":"De Veer","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2026.06.019_bib0006","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000677","article-title":"A nationwide study of primary biliary cholangitis prevalence, geographic distribution, and health care providers","volume":"9","author":"Levy","year":"2025","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.dld.2026.06.019_bib0007","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1002\/ueg2.70134","article-title":"Trends in primary biliary cholangitis: prospective cohort study from the European Reference Network Registry (R-LIVER)","volume":"13","author":"Gerussi","year":"2025","journal-title":"UEG J"},{"key":"10.1016\/j.dld.2026.06.019_bib0008","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/17474124.2025.2601220","article-title":"Primary biliary cholangitis (PBC): evolving approaches and expert perspectives","volume":"20","author":"Invernizzi","year":"2026","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0009","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2025.03.025","article-title":"Global Epidemiology of primary biliary cholangitis: an updated systematic review and meta-analysis","volume":"24","author":"Tan","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0010","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0011","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0012","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA response score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0013","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1080\/00365521.2019.1669702","article-title":"Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy","volume":"54","author":"Vespasiani-Gentilucci","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2026.06.019_bib0014","doi-asserted-by":"crossref","first-page":"390","DOI":"10.14309\/ajg.0000000000003029","article-title":"COBALT: a confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls","volume":"120","author":"Kowdley","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.06.019_bib0015","year":"2023","journal-title":"Ocaliva - ref | Eur Med Agency (EMA)"},{"key":"10.1016\/j.dld.2026.06.019_bib0016","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.06.019_bib0017","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.06.019_bib0018","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/HEP.0000000000001166","article-title":"Primary biliary cholangitis: personalizing second-line therapies","volume":"82","author":"Levy","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0019","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/HEP.0000000000000864","article-title":"Primary biliary cholangitis drug evaluation and regulatory approval: where do we go from here?","volume":"80","author":"Jones","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0020","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.06.019_bib0021","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/gut.49.2.276","article-title":"Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant","volume":"49","author":"Vleggaar","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.dld.2026.06.019_bib0022","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0023","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.06.019_bib0024","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study","volume":"65","author":"Trivedi","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.dld.2026.06.019_bib0025","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.06.019_bib0026","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.cgh.2020.08.006","article-title":"Measurement of gamma glutamyl transferase to determine risk of liver transplantation or death in patients with primary biliary cholangitis","volume":"19","author":"Gerussi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0027","doi-asserted-by":"crossref","first-page":"S309","DOI":"10.1016\/S0168-8278(25)00963-8","article-title":"THU-275 terminology, diagnosis and management of primary biliary cholangitis-autoimmune hepatitis variant syndrome (PBC-AIH): results from an international Delphi consensus process","volume":"82","author":"Gerussi","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0028","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jhep.2005.10.017","article-title":"Long term outcome and response to therapy of primary biliary cirrhosis\u2014autoimmune hepatitis overlap syndrome","volume":"44","author":"Chazouill\u00e8res","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0029","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/hep.21172","article-title":"Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis","volume":"43","author":"Wesierska-Gadek","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0031","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2025.09.024","article-title":"Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis","volume":"84","author":"Wong","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0032","article-title":"Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis","volume":"6","author":"Roberts","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2026.06.019_bib0033","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/hep.31810","article-title":"Accuracy of transient elastography in assessing fibrosis at diagnosis in na\u00efve patients with primary biliary cholangitis: a dual cut-off approach","volume":"74","author":"Cristoferi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0034","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis","volume":"77","author":"Corpechot","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0035","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u20132021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0036","article-title":"Spleen stiffness measurement predicts decompensation and rules out high-risk oesophageal varices in primary biliary cholangitis","volume":"6","author":"Rigamonti","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2026.06.019_bib0037","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 renewing consensus in portal hypertension","volume":"76","author":"De Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0038","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.cgh.2024.06.035","article-title":"Dynamics of liver stiffness measurement and clinical course of primary biliary cholangitis","volume":"22","author":"Lam","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0039","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch Path Anat Histol"},{"key":"10.1016\/j.dld.2026.06.019_bib0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1440-1827.2009.02500.x","article-title":"Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement","volume":"60","author":"Nakanuma","year":"2010","journal-title":"Pathol Int"},{"key":"10.1016\/j.dld.2026.06.019_bib0041","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0025-6196(11)63652-5","article-title":"Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis","volume":"73","author":"Scheuer","year":"1998","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.dld.2026.06.019_bib0042","first-page":"1257","article-title":"Symposium: advances in Liver Pathology [Abridged]: primary biliary cirrhosis","volume":"60","author":"Scheuer","year":"1967","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.dld.2026.06.019_bib0043","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2559.2006.02537.x","article-title":"Proposal of a new staging and grading system of the liver for primary biliary cirrhosis","volume":"49","author":"Hiramatsu","year":"2006","journal-title":"Histopathology"},{"key":"10.1016\/j.dld.2026.06.019_bib0044","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis","volume":"330","author":"Poupon","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.06.019_bib0045","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.06.019_bib0046","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0047","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.06.019_bib0048","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0049","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s00535-009-0051-9","article-title":"Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis","volume":"44","author":"Azemoto","year":"2009","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.dld.2026.06.019_bib0050","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.06.019_bib0051","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.06.019_bib0052","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should Be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.06.019_bib0053","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/HEP.0000000000000529","article-title":"Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: to what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?","volume":"79","author":"Corpechot","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0054","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/liv.15592","article-title":"Optimizing therapy in primary biliary cholangitis: alkaline phosphatase at six months identifies one-year non-responders and predicts survival","volume":"43","author":"Murillo Perez","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2026.06.019_bib0055","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/hep4.1567","article-title":"A systematic review of patient-reported outcomes in primary biliary cholangitis and primary sclerosing cholangitis","volume":"4","author":"Kim","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.dld.2026.06.019_bib0056","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1136\/gut.2005.065862","article-title":"Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis","volume":"54","author":"Jacoby","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.dld.2026.06.019_bib0057","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.dld.2010.01.004","article-title":"A short version of a HRQoL questionnaire for Italian and Japanese patients with primary biliary cirrhosis","volume":"42","author":"Montali","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2026.06.019_bib0058","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","article-title":"The 5-D itch scale: a new measure of pruritus: the 5-D itch scale","volume":"162","author":"Elman","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0060","first-page":"S335","article-title":"THU-340 validation of the clinical global impression severity scale for primary biliary cholangitis: a clinical trials outcome tool","volume":"82","author":"Hussain","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0061","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1016\/S0168-8278(25)01017-7","article-title":"THU-341 implementation of a clinical global impression severity scale for primary biliary cirrhosis: results of a hepatologist focussed training programme","volume":"82","author":"Hussain","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_sbref0062","author":"Umecrine Cognition"},{"key":"10.1016\/j.dld.2026.06.019_bib0063","article-title":"Real-world experience with obeticholic acid in patients with primary biliary cholangitis","volume":"3","author":"D\u2019Amato","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2026.06.019_bib0064","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/liv.15386","article-title":"Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid","volume":"42","author":"De Vincentis","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2026.06.019_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2024.05.008","article-title":"Development and validation of a scoring system to predict response to obeticholic acid in primary biliary cholangitis","author":"De Vincentis","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0066","article-title":"Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world","volume":"7","author":"Terracciani","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2026.06.019_bib0067","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI88894","article-title":"Distinct but complementary contributions of PPAR isotypes to energy homeostasis","volume":"127","author":"Dubois","year":"2017","journal-title":"J Clin Investig"},{"key":"10.1016\/j.dld.2026.06.019_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2023.100188","article-title":"PPAR agonists for the treatment of primary biliary cholangitis: old and new tales","volume":"6","author":"Colapietro","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.dld.2026.06.019_bib0069","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.06.019_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2008.03.007","article-title":"PPAR\u03b1 regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes","volume":"231","author":"Thulin","year":"2008","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.dld.2026.06.019_bib0071","series-title":"P30 treatment with elafibranor has no impact on bone health in patients with primary biliary cholangitis (PBC)","article-title":"P30 Treatment with elafibranor has no impact on bone health in patients with primary biliary cholangitis (PBC)","author":"Schattenberg","year":"2025"},{"key":"10.1016\/j.dld.2026.06.019_bib0072","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000845","article-title":"Fracture events in patients with primary biliary cholangitis during treatment with seladelpar in the phase III RESPONSE trial","volume":"9","author":"Vierling","year":"2025","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.dld.2026.06.019_bib0073","first-page":"A207","article-title":"P199 Long-term efficacy and safety of elafibranor in primary biliary cholangitis: interim results from the open-label extension of the ELATIVE\u00ae trial","author":"Prendergast","year":"2025","journal-title":"Posters BMJ Publ Group Ltd Br Soc Gastroenterol"},{"key":"10.1016\/j.dld.2026.06.019_bib0074","article-title":"Long-term efficacy and safety of selective ppar\u03b4 agonist seladelpar in primary biliary cholangitis: assure interim study results","author":"Levy","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.06.019_bib0075","unstructured":"Levy C., Hirschfield G.M., Lawitz E.J., et al. Sustained efficacy and safety of seladelpar for up to 36 months in patients with primary biliary cholangitis from the placebo-controlled RESPONSE study to the open-label ASSURE study."},{"key":"10.1016\/j.dld.2026.06.019_bib0076","unstructured":"Levy C., Akarca U., Alvares-da-Silva M.R., Andreone P., Arrese M., Bowlus C.L., et al. Long-term treatment with elafibranor leads to biochemical and symptomatic improvements for at least 3 years in patients with primary biliary cholangitis."},{"key":"10.1016\/j.dld.2026.06.019_bib0078","first-page":"4","article-title":"Sustained and clinically meaningful improvements in moderate to severe pruritus patients with PBC treated with Seladelpar: results from the ASSURE study up to 30 months","volume":"21","year":"2025","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.dld.2026.06.019_bib0079","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70041","article-title":"Fatigue and itch severity in patients with PBC and PSC : prospective analysis of two large cohorts","volume":"55","author":"Kruk","year":"2025","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.dld.2026.06.019_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.101945","article-title":"Primary biliary cholangitis has the worst quality of life indicators among the autoimmune liver diseases: a United States cohort","volume":"30","author":"Sierra","year":"2025","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0081","series-title":"P26 Elafibranor improves fatigue versus placebo in patients with primary biliary cholangitis (PBC), with limited correlation with pruritus: analyses from the phase III ELATIVE trial","article-title":"P26 Elafibranor improves fatigue versus placebo in patients with primary biliary cholangitis (PBC), with limited correlation with pruritus: analyses from the phase III ELATIVE trial","author":"Jones","year":"2025"},{"key":"10.1016\/j.dld.2026.06.019_bib0082","unstructured":"Swain M., del Pilar Schneider M., Plas P., et al. Elafibranor-associated changes in proteins linked to mitochondrial function correlate with fatigue improvement: proteomic results from the ELATIVE\u00ae trial."},{"key":"10.1016\/j.dld.2026.06.019_bib0083","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/liv.15039","article-title":"Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis","volume":"42","author":"Kremer","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2026.06.019_bib0084","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16222","article-title":"Second-line treatment for patients with primary biliary cholangitis: a systematic review with network meta-analysis","volume":"45","author":"Giannini","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2026.06.019_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102358","article-title":"PPAR agonists in PBC: where do we go from here? Or how to choose between the new and the old","volume":"48","author":"Tanaka","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.dld.2026.06.019_bib0086","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/apt.16618","article-title":"Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up","volume":"54","author":"Sorda","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2026.06.019_bib0087","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0088","unstructured":"L. Cristoferi, et al. Real-world experience of fibrates as second-line therapies in patients with primary biliary cholangitis: data from the Italian PBC Registry."},{"key":"10.1016\/j.dld.2026.06.019_bib0089","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41575-025-01135-y","article-title":"Bezafibrate for primary biliary cholangitis: time to act on the evidence","volume":"22","author":"Corpechot","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0090","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41575-026-01179-8","article-title":"The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view","volume":"23","author":"Jones","year":"2026","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0091","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41575-026-01177-w","article-title":"Reply to \u2018the ethics of unlicensed therapy use in primary biliary cholangitis: a counter view\u2019","volume":"23","author":"Corpechot","year":"2026","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0093","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis","volume":"76","author":"Vuppalanchi","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0094","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1161\/ATVBAHA.108.181610","article-title":"NADPH oxidases: functions and pathologies in the vasculature","volume":"30","author":"Lass\u00e8gue","year":"2010","journal-title":"ATVB"},{"key":"10.1016\/j.dld.2026.06.019_bib0095","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.freeradbiomed.2004.08.011","article-title":"Functional association of nox1 with p22phox in vascular smooth muscle cells","volume":"37","author":"Hanna","year":"2004","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.dld.2026.06.019_bib0096","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/liv.15596","article-title":"Setanaxib, a first-in-class selective NADPH oxidase 1\/4 inhibitor for primary biliary cholangitis: a randomized, placebo-controlled, phase 2 trial","volume":"43","author":"Invernizzi","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2026.06.019_bib0097","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000057","article-title":"Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial","volume":"7","author":"Jones","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.dld.2026.06.019_bib0099","article-title":"Calliditas\u2019 Phase IIb trial of PBC treatment meets primary endpoint","author":"VP","year":"2024","journal-title":"Clin Trials Arena"},{"key":"10.1016\/j.dld.2026.06.019_bib0100","unstructured":"Kowdley K.V., Minuk G.Y., Pagadala M.R., Gulamhusein A., Swain M.G., Neff G.W., et al. The nonsteroidal farnesoid X receptor (FXR) agonist cilofexor improves liver biochemistry in patients with primary biliary cholangitis (PBC): a phase 2, randomized, placebo-controlled trial."},{"key":"10.1016\/j.dld.2026.06.019_bib0101","article-title":"Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis","volume":"4","author":"Schramm","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2026.06.019_bib0102","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jhep.2022.10.007","article-title":"Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases\u2020","volume":"78","author":"Nevens","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1698833","article-title":"Primary biliary cholangitis. Treatment options in 2025. A narrative review","volume":"16","author":"Angelara","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.dld.2026.06.019_bib0104","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.3390\/biomedicines10082033","article-title":"Update on the pharmacological treatment of primary biliary cholangitis","volume":"10","author":"Floreani","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.dld.2026.06.019_bib0105","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","article-title":"Primary biliary cholangitis","volume":"404","author":"Tanaka","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.06.019_bib0106","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.3390\/jcm10081763","article-title":"The management of cholestatic liver diseases: current therapies and emerging new possibilities","volume":"10","author":"Mazzetti","year":"2021","journal-title":"JCM"},{"key":"10.1016\/j.dld.2026.06.019_bib0107","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejim.2024.01.030","article-title":"Treatment in primary biliary cholangitis: beyond ursodeoxycholic acid","volume":"124","author":"Van Hooff","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.dld.2026.06.019_bib0108","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.cgh.2022.10.032","article-title":"GLIMMER: a randomized phase 2b dose-ranging trial of Linerixibat in primary biliary cholangitis patients with pruritus","volume":"21","author":"Levy","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0109","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2468-1253(25)00192-X","article-title":"Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Hirschfield","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0111","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.06.019_bib0112","article-title":"Optimizing care in primary biliary cholangitis: current treatments and the second-line decision","author":"Choi","year":"2025","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2026.06.019_bib0115","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s10620-019-05786-1","article-title":"Outcomes of liver transplant candidates with primary biliary cholangitis: the data from the scientific registry of transplant recipients","volume":"65","author":"Sayiner","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2026.06.019_bib0116","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/j.ajt.2023.02.006","article-title":"OPTN\/SRTR 2021 annual data report: liver","volume":"23","author":"Kwong","year":"2023","journal-title":"Am J Transplant"},{"key":"10.1016\/j.dld.2026.06.019_bib0117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0118","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gut.20.2.137","article-title":"Serum bilirubin: a prognostic factor in primary biliary cirrhosis","volume":"20","author":"Shapiro","year":"1979","journal-title":"Gut"},{"key":"10.1016\/j.dld.2026.06.019_bib0119","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1600-6143.2004.00703.x","article-title":"The survival benefit of liver transplantation","volume":"5","author":"Merion","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.dld.2026.06.019_bib0120","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bpg.2018.06.006","article-title":"Risk stratification and prognostic modelling in primary biliary cholangitis","volume":"34-35","author":"Goet","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.dld.2026.06.019_bib0121","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/hep.23095","article-title":"Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers\u2020","volume":"50","author":"Cavazza","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0122","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.dld.2022.03.002","article-title":"Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma","volume":"54","author":"Giannini","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2026.06.019_bib0123","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.06.019_bib0124","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s10620-020-06498-7","article-title":"Incidence of hepatocellular carcinoma in primary biliary cholangitis: a systematic review and meta-analysis","volume":"66","author":"Natarajan","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2026.06.019_bib0125","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","author":"Sangro","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0126","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jhep.2020.12.029","article-title":"We need stronger evidence for (or against) hepatocellular carcinoma surveillance","volume":"74","author":"Jepsen","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0127","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0129","doi-asserted-by":"crossref","first-page":"361","DOI":"10.14309\/ajg.0000000000000056","article-title":"Baveno-VI\u2013guided prediction of esogastric varices in primary biliary cholangitis","volume":"114","author":"Pariente","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.06.019_bib0130","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41395-018-0265-7","article-title":"Non-invasive prediction of high-risk varices in patients with primary biliary cholangitis and primary sclerosing cholangitis","volume":"114","author":"Moctezuma-Velazquez","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.06.019_bib0131","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.cgh.2024.10.020","article-title":"Noninvasive assessment of portal hypertension in patients with primary biliary cholangitis is affected by severity of cholestasis","volume":"23","author":"Calvaruso","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0132","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.31559","article-title":"Reproductive health and liver disease: practice guidance by the American Association for the Study of Liver Diseases","volume":"73","author":"Sarkar","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0133","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jhep.2023.03.006","article-title":"EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy","volume":"79","author":"Williamson","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0134","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ajg.2015.430","article-title":"ACG Clinical guideline: liver disease and pregnancy","volume":"111","author":"Tran","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.06.019_bib0135","article-title":"Quality of life in patients with variant syndromes of autoimmune liver diseases\u2014a cross-sectional multicentre study","volume":"46","author":"Uhlenbusch","year":"2026","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2026.06.019_bib0136","article-title":"Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy","volume":"6","author":"Stoelinga","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2026.06.019_bib0137","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001793","article-title":"Definition, diagnosis, and treatment of primary biliary cholangitis - autoimmune hepatitis (PBC-AIH) variant: an international expert delphi consensus","author":"Gerussi","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0138","doi-asserted-by":"crossref","first-page":"7047","DOI":"10.3390\/jcm12227047","article-title":"Primary biliary cholangitis (PBC)-autoimmune Hepatitis (AIH) Variant syndrome: clinical features, response to therapy and long-term outcome","volume":"12","author":"Graf","year":"2023","journal-title":"JCM"},{"key":"10.1016\/j.dld.2026.06.019_bib0139","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/ajg.2009.126","article-title":"The serological profile of the autoimmune Hepatitis\/primary biliary cirrhosis overlap syndrome","volume":"104","author":"Muratori","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2026.06.019_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103163","article-title":"Immunosuppression induces regression of fibrosis in primary biliary cholangitis with moderate-to-severe interface hepatitis","volume":"143","author":"Wang","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.dld.2026.06.019_bib0141","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cgh.2013.09.021","article-title":"Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune Hepatitis","volume":"12","author":"Ozaslan","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0142","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3390\/jcm11030768","article-title":"The effect of fibrates on kidney function and chronic Kidney disease progression: a systematic review and meta-analysis of randomised studies","volume":"11","author":"Hadjivasilis","year":"2022","journal-title":"JCM"},{"key":"10.1016\/j.dld.2026.06.019_bib0143","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jcp.25804","article-title":"The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice","volume":"233","author":"Derosa","year":"2018","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.dld.2026.06.019_bib0144","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/hep.30904","article-title":"Efficacy and safety of 3-year denosumab therapy for osteoporosis in patients with autoimmune liver diseases","volume":"71","author":"Arase","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0146","unstructured":"Global consensus primary biliary cholangitis (PBC) endpoints - EASL\/AASLD Joint Program | The Liver Meeting | AASLD. https:\/\/www.aasld.org\/the-liver-meeting\/sessions\/global-consensus-primary-biliary-cholangitis-pbc-endpoints\u2014easl-aasld-joint-program-815239. Accessed March 10, 2026."},{"key":"10.1016\/j.dld.2026.06.019_bib0147","unstructured":"M. Scaravaglio, A. Martins, C.L. Bowlus, C.A. Couto, C. Corpechot, B.E. Hansen, G.M. Hirschfield, D.E.J. Jones, M.J. Mayo, A. Villamil, J. Willemse, C. Levy, M. Carbone, A. Lle\u00f3. A global Delphi consensus involving patients, industry, clinicians, and regulators on surrogate endpoints and real-world evidence in primary biliary cholangitis: an EASL-AASLD framework for therapeutic development."},{"key":"10.1016\/j.dld.2026.06.019_bib0148","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2026.03.038","article-title":"EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis","author":"Levy","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2026.06.019_bib0149","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/hep.31613","article-title":"Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate","volume":"73","author":"Smets","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0150","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/apt.16336","article-title":"Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis","volume":"53","author":"Soret","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2026.06.019_bib0151","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/apt.18004","article-title":"Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: stratifying the impact of add-on fibrates in real-world practice","volume":"59","author":"G\u00f3mez","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2026.06.019_bib0152","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"De Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2026.06.019_bib0153","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hep4.1305","article-title":"A randomized, controlled, phase 2 study of Maralixibat in the treatment of itching associated with primary biliary cholangitis","volume":"3","author":"Mayo","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.dld.2026.06.019_bib0154","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.06.019_bib0155","unstructured":"Heneghan M.A., Shiffman M.L., Weinstein D., et al. OS-059 Volixibat for the treatment of cholestatic pruritus in primary biliary cholangitis: an adaptive, randomized, placebo-controlled phase 2b trial (VANTAGE): 28-week interim results."},{"key":"10.1016\/j.dld.2026.06.019_bib0156","unstructured":"Kowdley K.V., Shiffman M.L., Weinstein D., et al. Volixibat leads to improvements in fatigue and sleep for adults with primary biliary cholangitis: data from VANTAGE."},{"key":"10.1016\/j.dld.2026.06.019_bib0157","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/hep.510290229","article-title":"Quality of life before and after liver transplantation for cholestatic liver disease","volume":"29","author":"Gross","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2026.06.019_bib0158","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000440757","article-title":"Fatigue in primary biliary cirrhosis: prevalence, pathogenesis and management","volume":"33","author":"Jopson","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.dld.2026.06.019_bib0159","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11901-019-00458-0","article-title":"Management of fatigue in primary biliary cholangitis","volume":"18","author":"Khanna","year":"2019","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.dld.2026.06.019_bib0160","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4254\/wjh.v14.i6.1111","article-title":"Understanding fatigue in primary biliary cholangitis: from pathophysiology to treatment perspectives","volume":"14","author":"Lynch","year":"2022","journal-title":"WJH"},{"key":"10.1016\/j.dld.2026.06.019_bib0161","article-title":"A home-based exercise programme attenuates fatigue in primary biliary cholangitis: results from the EXCITED clinical trial","volume":"6","author":"Freer","year":"2024","journal-title":"JHEP Rep"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826007851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826007851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:36:48Z","timestamp":1786707408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865826007851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":152,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1590865826007851"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.06.019","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AISF practice guidance on the treatment of primary biliary cholangitis: A 2026 update","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}